ESC Premium Access

Understanding epigenetics - The potential rationale for BET inhibition in management of cardiovascular disease.

Topic: Secondary Prevention
Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Resverlogix

Congress Session

About the speaker

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)
5 presentations
0 follower

4 more presentations in this session

Introduction - LDL-c: done deal, next epigenetics?

Speaker: Professor U. Laufs (Leipzig, DE)

Thumbnail

The real residual risk in patients with cardiovascular disease and diabetes: the promise of epigenetics.

Speaker: Professor E. Stroes (Amsterdam, NL)

Thumbnail

A clinical view on BET inhibition in targeting residual risk in cardiovascular disease and diabetes.

Speaker: Professor K. Ray (London, GB)

Thumbnail

Discussion and summary - LDL-c: done deal, next epigenetics? .

Speaker: Professor U. Laufs (Leipzig, DE)

Thumbnail

Access the full session

LDL-c: done deal, next epigenetics? (EBAC Accredited)

Speakers: Doctor J. Plutzky, Professor U. Laufs, Professor E. Stroes, Professor K. Ray, Professor U. Laufs
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk